Financial Data and Key Metrics Changes - The company reported sales of $204.6 million for Q1 2025, a 3% increase from $197.9 million in the prior year [15] - Adjusted EBITDA for the quarter was $12.3 million, representing 6% of sales, up from $6.1 million or 3.1% of sales in Q1 2024 [16] - GAAP net loss was $1.4 million or negative $0.04 per share, compared to a net loss of $4.7 million or negative $0.14 per share in the previous year [15][16] Business Line Data and Key Metrics Changes - Fleet Vehicles and Services segment achieved sales of $96.1 million, down 11% from $107.8 million a year ago, reflecting softness in parcel end markets [17] - Specialty Vehicles segment delivered sales of $82.2 million, a 9% decrease from $90.1 million in the prior year, with adjusted EBITDA margins remaining in the high teens [18] Market Data and Key Metrics Changes - The FES backlog was $245.3 million at quarter end, down 31% versus the prior year and flat compared to year-end 2024 [18] - Specialty Vehicles backlog was $90 million at quarter end, up 8% versus the prior year and up 31% versus year-end, driven primarily by high content service truck bodies [19] Company Strategy and Development Direction - The company is focused on customer-centric innovation and expanding its product portfolio, particularly in electric vehicles and service trucks [6][10] - The proposed merger with Abbe Schmidt is expected to create a leading global force in the specialty vehicles industry, driving growth in high-margin markets [23][24] Management's Comments on Operating Environment and Future Outlook - Management remains cautious about the timing of recovery in the parcel and motorhome markets but expects approximately 70% of full-year adjusted EBITDA to be delivered in the second half of the year [21] - The company is affirming its 2025 outlook with sales projected between $870 million to $970 million and adjusted EBITDA of $62 million to $72 million [20][21] Other Important Information - The company incurred $2.2 million in transaction costs related to the proposed merger with Abbe Schmidt [16] - The merger is anticipated to be approved in a special meeting of shareholders in mid-2025 [24] Q&A Session Summary Question: Update on BlueArc vehicle orders and revenue - Management confirmed that the order for 150 vehicles for FedEx is in process, with some revenue carryover expected into Q2 [29] Question: Impact of tariffs on guidance - Management stated that they are closely monitoring tariffs and have implemented pricing strategies to mitigate risks, which is reflected in their unchanged guidance [31][34] Question: Trends in Abbe Schmidt's business - Management refrained from commenting on Abbe Schmidt's financials as the S-four filing is still with the SEC [37] Question: Customer order timing related to tariffs - Management indicated that there was no significant pull-forward of orders due to tariff concerns [41] Question: Outlook for parcel and final mile vehicles - Management noted an increase in quoting activity from parcel customers, suggesting a potentially better second half of the year [43] Question: Update on battery supply chain - Management expressed confidence in the battery supply chain, stating that performance is meeting expectations and there are no issues in the field [49]

Meeting further adjourned to May 1, 2025 at 8:00 a.m. Central TimeHOUSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Amplify Energy Corp. (NYSE: AMPY) (“Amplify” or the “Company”) today announced that it intends to open and immediately adjourn its reconvened Special Meeting of Stockholders (the “Special Meeting”) relating to the Company’s proposed merger with Juniper Capital’s upstream Rocky Mountain portfolio companies. There will be no voting or other matters conducted at the meeting on April 23, 2025, and the C ...

Core Viewpoint - The merger between Alumis Inc. and ACELYRIN, INC. has been amended to provide increased ownership for ACELYRIN stockholders, with the revised exchange ratio allowing Alumis stockholders to own approximately 52% and ACELYRIN stockholders to own approximately 48% of the combined company on a fully diluted basis, maximizing potential value for both parties [1][2]. Company Overview - Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated diseases using a precision approach [10]. - ACELYRIN, INC. is a late-stage clinical biopharma company dedicated to accelerating the development and commercialization of transformative medicines, with its lead program targeting thyroid eye disease [11]. Merger Details - The amended agreement allows ACELYRIN stockholders to receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned, representing a significant increase in ownership compared to the original merger terms [2]. - The merger is expected to create a leading clinical-stage immunology company with a diversified portfolio of product candidates, enhancing financial flexibility and advancing a late-stage pipeline [5][3]. Financial Position - Alumis reported a pro forma cash position of approximately $737 million as of December 31, 2024, which is expected to support the combined company's pipeline and operational needs into 2027 [5]. - Stockholders representing approximately 62% of Alumis voting common stock and about 24% of ACELYRIN common stock have entered into voting agreements in support of the transaction [6]. Upcoming Events - A Special Meeting of Stockholders for both companies is scheduled for May 13, 2025, where stockholders will vote on the merger [8][7].

Today, Hess (NYSE: HES ) is not just an industry pioneer , but a dramatically reformed player who has gone through a transformation from a vertically integrated oil giant with its own refineries and a network of fillingMy professional background spans multiple continents and includes experience in private banking, corporate finance, and strategic advisory. For several years, I developed and led a private banking department in Dubai, where I crafted tailored investment solutions to meet the unique needs of a ...

Core Points - Cara Therapeutics, Inc. has announced a 1-for-3 reverse stock split of its outstanding shares of common stock [1] - The company's common stock will begin trading under the new name "Tvardi Therapeutics, Inc." and the new symbol "TVRD" following the merger with Tvard Therapeutics, Inc. [2] - The reverse stock split was approved by stockholders and will reduce the number of outstanding shares from approximately 4.6 million to approximately 1.5 million [3][4] Company Overview - Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies targeting STAT3 for fibrosis-driven diseases [7] - Cara Therapeutics is a biopharmaceutical company that has developed an IV formulation of difelikefalin for treating moderate-to-severe pruritus associated with advanced kidney disease [8]

Company Overview - The Shyft Group, Inc. is a leader in specialty vehicle manufacturing, assembly, and upfit for commercial, retail, and service specialty vehicle markets in North America [4] - Shyft operates two core business units: Shyft Fleet Vehicles and Services™ and Shyft Specialty Vehicles™ [4] - The company reported sales of $786 million in 2024 and employs approximately 2,900 people across various facilities [4] Merger Announcement - Aebi Schmidt Group has filed a registration statement on Form S-4 with the SEC regarding a proposed merger with Shyft [1][2] - The merger is expected to close in mid-2025, subject to SEC approval and shareholder approval from Shyft [2] - Upon completion, the combined company will be named Aebi Schmidt Group and will trade on Nasdaq under the ticker symbol "AEBI" [3][7] Financial Projections - The registration statement includes pro forma U.S. GAAP financial results for 2024, projecting combined revenues of $1.9 billion and adjusted EBITDA of $148 million [2][7] Aebi Schmidt Group Overview - Aebi Schmidt is a global leader in intelligent solutions for infrastructure maintenance, generating over 1 billion EUR in net sales in 2024 [5] - The company employs around 3,000 people and operates in 16 sales organizations and over a dozen production facilities worldwide [5]

Renasant (RNST) Q4 2024 Earnings Call January 29, 2025 10:00 AM ET Company Participants Kelly Hutcheson - Executive VP & Chief Accounting OfficerMitchell Waycaster - CEO & Executive Vice ChairmanKevin Chapman - President & COOJames Mabry - Executive VP & CFOJoseph Yanchunis - Senior Equity Research AssociateWill Jones - Associate Vice PresidentMatt Olney - Managing DirectorDavid Meredith - Senior EVP & Chief Credit OfficerDavid Bishop - Director Conference Call Participants Stephen Scouten - Managing Direct ...